Tejas Patil

Also affiliated with University of Colorado Denver

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 20 papers. Top paper: “Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers”.

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist(2022)10.1093/oncolo/oyac080

N/A

1.7DataRank · unranked

49 citations

Christina S. Baik, Jessica R. Bauman, Jill Gilbert, Marcia S. Brose, Juneko E. Grilley‐Olson +13 more

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Journal of Clinical Oncology(2024)10.1200/jco.24.00071

N/A

1.4DataRank · unranked

60 citations

Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen Shiboski +19 more

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Cancer(2023)10.1002/cncr.35036

N/A

0.937DataRank · unranked

25 citations

Lin Shen, David S. Hong, Ray McDermott, Vicki L. Keedy, Michela Casanova +19 more

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3497

N/A

0.564DataRank · unranked

42 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz +16 more

Prediction of cancer treatment response from histopathology images through imputed transcriptomics.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1551

N/A

0.292DataRank · unranked

6 citations

Gal Dinstag, Leandro C. Hermida, Doreen S. Ben-Zvi, Chani Stossel, Tejas Patil +15 more

Prediction of cancer treatment response from histopathology images through imputed transcriptomics

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.06.07.495219

N/A

0DataRank · unranked

9 citations

Gal Dinstag, Leandro C. Hermida, Doreen S. Ben-Zvi, Efrat Elis, Katherine Caley +25 more

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21112

N/A

0DataRank · unranked

0 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Anna Wurtz, Zofia Piotrowska, Andrew J. Piper‐Vallillo +13 more

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

npj Precision Oncology(2023)10.1038/s41698-023-00381-0

N/A

0DataRank · unranked

8 citations

Tejas Patil, M Sakamoto

Prediction of cancer treatment response from histopathology images through imputed transcriptomics

Research Square(2023)10.21203/rs.3.rs-3193270/v1

N/A

0DataRank · unranked

6 citations

Danh-Tai Hoang, Gal Dinstag, Leandro C. Hermida, Doreen S. Ben-Zvi, Efrat Elis +25 more

A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

Nature Cancer(2024)10.1038/s43018-024-00793-2

N/A

0DataRank · unranked

141 citations

Gal Dinstag, Eldad D. Shulman, Leandro C. Hermida, Doreen S. Ben-Zvi, Efrat Elis +26 more

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Journal of Clinical Oncology(2024)10.1200/jco.23.02668

N/A

0DataRank · unranked

49 citations

Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall +19 more

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.01.012

N/A

0DataRank · unranked

42 citations

So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances A. Shepherd, Chao Xu +52 more

The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations

Lung Cancer(2024)10.1016/j.lungcan.2024.108040

N/A

0DataRank · unranked

10 citations

Dexiang Gao, Alexander Watson, M Sakamoto, Yunan Nie, A.J. Gibson +13 more

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

JTO Clinical and Research Reports(2024)10.1016/j.jtocrr.2024.100637

N/A

0DataRank · unranked

8 citations

Alyse Staley, Yunan Nie, M Sakamoto, Margaret Stalker, James Jurica +17 more

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.06.015

N/A

0DataRank · unranked

13 citations

Tejas Patil, Kedar Kirtane, Thereasa A. Rich, Carin R. Espenschied, Caroline Weipert +5 more

Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100870

N/A

0DataRank · unranked

0 citations

Alyse Staley, Benjamin A. Yoder, Sean J. Iwamoto, Vida Alami, Erin L. Schenk +4 more

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00510

N/A

0DataRank · unranked

3 citations

Jose M. Pacheco, Anastasios Dimou, W. Thomas Purcell, Candice Rossi, Paul A. Bunn +4 more

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100187

N/A

0DataRank · unranked

33 citations

Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang +13 more

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

npj Precision Oncology(2021)10.1038/s41698-021-00231-x

N/A

0DataRank · unranked

11 citations

Tejas Patil, Anh T. Le, Kurtis D. Davies, Peter Brzeskiewicz, Hala Nijmeh +5 more

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Frontiers in Oncology(2022)10.3389/fonc.2021.788245

N/A

0DataRank · unranked

6 citations

Yunan Nie, Dara L. Aisner, David Ross Camidge, Tejas Patil